Non-spherocytic hemolytic anemia due to hexokinase deficiency
MONDO:0009340Nonspherocytic hemolytic anemia due to hexokinase deficiency (NSHA due to HK1 deficiency) is a very rare conditionmainly characterized by severe, chronic hemolysis, beginning in infancy. Approximately 20 cases of this condition have been described to date. Signs and symptoms of hexokinase deficiency are very similar to those of pyruvate kinase deficiency but anemia is generally more severe. Some affected individuals reportedly have had various abnormalities in addition to NSHA including multiple malformations, panmyelopathy, and latent diabetes.Itcan be caused by mutations in the HK1 gene and is inherited in an autosomal recessive manner. Treatment may include red cell transfusions for those with severe anemia.
Also known as: anemia, congenital, nonspherocytic hemolytic, 5, hexokinase deficient, hemolytic anaemia due to hexokinase deficiency, hemolytic anemia due to hexokinase deficiency, hemolytic anemia, nonspherocytic, due to hexokinase deficiency, nonspherocytic hemolytic anaemia due to hexokinase deficiency, nonspherocytic hemolytic anemia due to hexokinase deficiency, hexokinase deficiency hemolytic anaemia, hexokinase deficiency hemolytic anemia
20 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New blood treatment could block zika in transfusions
Disease control OngoingThis study tests a special treatment for red blood cells that aims to kill the Zika virus, making transfusions safer. About 692 people who need blood transfusions will receive either treated or standard blood. The goal is to see if the treated blood works just as well and is safe…
Phase: PHASE3 • Sponsor: Cerus Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cord blood matching method could expand transplant access for blood cancer patients
Disease control OngoingThis study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than …
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 26, 2026 13:02 UTC